Phortas is pleased to announce its participation in Advanced Therapies Week 2026 , the leading global conference dedicated to Cell and Gene Therapy . The event will take place from 09–12 February 2026  at the San Diego Convention Center , bringing together key stakeholders from across the advanced therapies ecosystem. Advanced Therapies Week is widely recognised as a central meeting point for innovation and collaboration in the field of cell and gene therapies. Each year, it

Phortas‘ Director, Senior Regulatory Lead Dr. Darius-Jean Namdjou, recently attended the annual open meeting of the European Network of Paediatric Research at EMA (Enpr-EMA), held in Amsterdam in person. The event brought together key stakeholders in the European pediatric research landscape, spanning from academic excellence centers to ethicists, regulators and industry. Key highlights included: Industry case studies on up-to-date approaches to paediatric clinical trial des

At  Phortas , we are committed to advancing patient-centric and globally relevant drug development.  We’re pleased to announce that on 11 December 2025 at 13:00 CET,  Dr. Darius-Jean Namdjou , will present on a topic of increasing importance for our industry: the need for greater diversity, inclusion, and patient representation in clinical trials. 🙂  Underrepresentation across gender, ethnicity, socioeconomic status, and other factors continues to influence the quality and a

For the last 7 years, we’ve helped drug companies get their products through regulatory agencies in the US, Europe, Japan, and beyond. CROs are great at running trials on a big scale, but when the real hurdle is the regulator, a specialist team like ours often moves things forward faster and with fewer headaches. What We Do, Day to Day Phortas only handles your regulatory work. That means: Writing briefing packages and running practice sessions for FDA, EMA, or PMDA meetings.

We are proud to share that Dr. Darius-Jean Namdjou, Director and Senior Regulatory Lead at Phortas, participated in the General Assembly Meeting of ERDERA, held from 29–31 October 2025 at the Amsterdam University Medical Center (UMC). ERDERA – the European Rare Diseases Research Alliance  – is a European partnership that unites over 170 public and private organisations across 37 countries around a common goal: transforming cutting-edge science into tangible benefits for the t

Phortas is proud to announce that at the end of July 2025 our Quality Management System was officially certified according to the ISO9001:2015 standard. This certification reinforces our commitment to delivering the highest quality standards in regulatory affairs consulting and development consulting. It brings clear benefits to our clients, including: Increased customer trust and satisfaction – Clients can rely on our structured processes and consistent service delivery liv

Phortas is thrilled to be attending and sharing our expertise at this year’s BIO International Convention , taking place in Boston from...

Our Managing Director, Jasmina Savic , will be leading the session "Accelerating Clinical Trials in the EU"  on 14 May 2025 at this...

We are excited to share that Dr. Darius-Jean Namdjou, our Director, Senior Regulatory Lead at Phortas, recently participated in the...

We are thrilled to share that Jasmina Savic, our Managing Director at Phortas, recently participated in the European Medicines Agency...